Skip to content

Study · Ex vivo tissue · bovine and porcine · 1998

5 results

Identification of a pituitary growth hormone-releasing peptide (GHRP) receptor subtype by photoaffinity labeling.

Ong H, McNicoll N, Escher E, Collu R, Deghenghi R, Locatelli V, Ghigo E, Muccioli G, Boghen M, Nilsson M

Endocrinology1 Jan 1998Cited by 68 (Europe PMC)

PMID9421445 (opens in a new tab)DOI10.1210/endo.139.1.5811 (opens in a new tab)PepBankPUB-09421445
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueActivity measurement

    In anterior pituitary membranes, MK-0677 displaced the photolabeled band with an apparent ED50 of 2x10(-5) M.

    In plain wordsIn lab tests, MK-0677 displaced the labeled receptor band in pituitary membranes.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    DecreasePhotolabeled band displacement ED50
    Study

    human, bovine and porcinen: not reported in source

    anterior pituitary membranes
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Hexarelin and the spiroindoline sulfonamide MK-0677 displaced the Mr-57,000 photolabeled band with an apparent ED50 of 6x10(-7) M and 2x10(-5) M respectively.
    1 context sentence
    Summary · context
    Using this photoactivatable ligand, we have specifically labeled a protein with an apparent Mr of 57,000 in human, bovine and porcine anterior pituitary membranes.
  2. 02LabIn vitro (cell-free)Activity measurement

    Hexarelin displaced the photolabeled Mr-57,000 band in pituitary membranes with an apparent ED50 of 6x10(-7) M.

    In plain wordsIn lab tests, hexarelin competed with the label for binding to the 57,000-mass pituitary protein.

    Peptide
    Hexarelin
    Outcome
    Not applicableDisplacement of the photolabeled Mr-57,000 band
    Study

    human, bovine, porcinen: not reported in source

    Anterior pituitary membranes
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Hexarelin and the spiroindoline sulfonamide MK-0677 displaced the Mr-57,000 photolabeled band with an apparent ED50 of 6x10(-7) M and 2x10(-5) M respectively.
    1 context sentence
    Summary · context
    Hexarelin, an analogue of GHRP-6, in which D-Tryptophan has been replaced by its 2-methyl derivative, is known to release growth hormone (GH) in vivo and in vitro by direct action on receptors present in anterior pituitary cells.

Studies that did not test the peptide alone3

In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Hexarelin.

  1. 03AnimalNot a test of Hexarelin aloneAnimal study (in vivo)Activity measurement

    In neonate rats, the photoactivatable derivative Tyr-Bpa-Ala-Hexarelin was fully active in releasing GH.

    In plain wordsIn newborn rats, a modified hexarelin molecule used for labelling was fully active in releasing growth hormone.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH release by the photoactivatable hexarelin derivative in vivo
    Study

    ratn: not reported in source

    Neonate rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    This derivative was shown to be fully active in the release of GH in vivo with neonate rats.
    2 context sentences
    Summary · context
    In order to document such an hypothesis, we have used a new photoactivatable derivative of Hexarelin, Tyr-Bpa-Ala-Hexarelin.
    Summary · context
    Hexarelin, an analogue of GHRP-6, in which D-Tryptophan has been replaced by its 2-methyl derivative, is known to release growth hormone (GH) in vivo and in vitro by direct action on receptors present in anterior pituitary cells.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  2. 04LabNot a test of Hexarelin aloneIn vitro (cell-free)Mechanism

    The photoactivatable hexarelin derivative specifically labeled a protein of apparent Mr 57,000 in human, bovine and porcine anterior pituitary membranes.

    In plain wordsIn lab tests, a modified hexarelin molecule attached to a protein of about 57,000 mass in human, cow and pig pituitary membranes.

    Peptide
    Hexarelin
    Outcome
    Not applicablePhotolabeling of a pituitary membrane protein
    Study

    human, bovine, porcinen: not reported in source

    Anterior pituitary membranes
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    Using this photoactivatable ligand, we have specifically labeled a protein with an apparent Mr of 57,000 in human, bovine and porcine anterior pituitary membranes.
    1 context sentence
    Summary · context
    Hexarelin, an analogue of GHRP-6, in which D-Tryptophan has been replaced by its 2-methyl derivative, is known to release growth hormone (GH) in vivo and in vitro by direct action on receptors present in anterior pituitary cells.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  3. 05LabNot a test of Hexarelin aloneIn vitro (cell-free)Mechanism

    The photoactivatable hexarelin derivative, with covalent incorporation above 60%, allowed identification of a pituitary GHRP receptor subtype apparently distinct from the cloned GH secretagogue receptor.

    In plain wordsIn lab tests, a modified hexarelin molecule helped identify a pituitary receptor that appears different from the cloned GH secretagogue receptor.

    Peptide
    Hexarelin
    Outcome
    Not applicableIdentification of a pituitary GHRP receptor subtype
    Study

    human, bovine, porcinen: not reported in source

    Anterior pituitary membranes
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Measurements

    Covalent incorporation of Bpa residue
    > 60%
    photoactivatable hexarelin derivative

    Source sentences

    Summary
    Taking into account the high efficiency (>60%) of covalent incorporation of the Bpa residue, this photoactivatable Hexarelin derivative has allowed the identification of a pituitary GHRP receptor subtype, which is apparently distinct from the recently cloned GH secretagogue receptor.
    1 context sentence
    Summary · context
    Hexarelin, an analogue of GHRP-6, in which D-Tryptophan has been replaced by its 2-methyl derivative, is known to release growth hormone (GH) in vivo and in vitro by direct action on receptors present in anterior pituitary cells.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    14 Oct 2026, 01:46 UTC

    Study data updated · source update from Europe PMC

  2. Version 3

    13 Oct 2026, 21:44 UTC

    Study results updated

  3. Version 2

    13 Oct 2026, 16:31 UTC

    Study data updated · source update from Europe PMC

  4. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.